QOL an important endpoint among patients treated for NSCLC

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1346, 2002-01, pp. : 5-5

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

QOL an important endpoint among patients treated for NSCLC

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 371, 2002-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Erlotinib improves QOL in NSCLC

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 512, 2006-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Erlotinib improves QOL in NSCLC

Inpharma, Vol. 1, Iss. 1557, 2006-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite

Mannitol [Bronchitol] may improve mucus clearance and QOL among patients with bronchiectasis

Inpharma, Vol. 1, Iss. 1604, 2007-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite

QOL improves with additional SRL 172 in NSCLC

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 454, 2004-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite